American journal of cancer research最新文献

{"title":"Astragalus polysaccharides inhibits nasopharyngeal carcinoma progression through the mediation of the Akt/mTOR pathway and the induction of oxidative stress.","authors":"Ruojin Chen, Junyong Chen, Xuan Chen, Shangli Chen, Haiying Jia, Zhi Tang","doi":"10.62347/QSZR3302","DOIUrl":"10.62347/QSZR3302","url":null,"abstract":"<p><p>To investigate whether astragalus polysaccharides (APS) can inhibit the progression of nasopharyngeal carcinoma (NPC) and its underlying mechanisms, we conducted both cell and animal experiments. In NPC tissues and cell lines, the level of SNHG12 was significantly elevated, and high levels of SNHG12 were associated with advanced TNM staging, as well as increased cell viability and invasiveness. We further explored the mechanism by which SNHG12 promotes NPC progression and found multiple binding sites between SNHG12 and miR-30a-3p (miR-30a). The expression of miR-30a was significantly decreased in NPC tissues and cell lines, showing a strong negative correlation with SNHG12 levels. Moreover, SNHG12 could counteract the anti-cancer effects of miR-30a, enhancing the viability and migratory ability of CNE-2 cells. Further studies revealed that miR-30a could target and inhibit AKT3 levels, while SNHG12 could antagonize miR-30a and restore AKT3 levels. Thus, SNHG12 can regulate the malignant biological characteristics of NPC by targeting the miR-30a/AKT3 axis. In animal experiments, we found that APS can downregulate SNHG12 and upregulate miR-30a in tumor tissues, effectively suppressing NPC progression. Additionally, APS demonstrated significant antioxidant effects. Therefore, APS can inhibit oxidative stress and suppress NPC progression by targeting the SNHG12/miR-30a/AKT3 signaling pathway.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2469-2481"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The correlation between ALDH2 rs671 polymorphism and clinical prognosis in alcoholic liver disease-related hepatocellular carcinoma after curative resection.","authors":"Chih-Jan Ko, Wen-Lung Wang, Hung-Yu Lin, Pei-Min Hsieh, Szu-Ying Chen, Steven Yu Lin, Kuang-Chun Hu, James Yu Lin, Li-Wei Chou, Yaw-Sen Chen, Yu-Wei Huang, Chen-Ti Wang, Wen-Chao Ho, Chih-Wen Lin","doi":"10.62347/EVBS5360","DOIUrl":"10.62347/EVBS5360","url":null,"abstract":"<p><p>Whether the aldehyde dehydrogenase 2 (ALDH2) rs671 polymorphism predicts clinical prognosis in alcoholic liver disease (ALD)-related hepatocellular carcinoma (HCC) after hepatectomy remains unclear. Hence, this study aims to investigate the association between ALDH2 rs671 polymorphism and HCC recurrence and mortality in patients with ALD-related HCC who underwent hepatectomy. We also explored the risk factors for HCC recurrence and mortality in this population of patients. This retrospective cohort study enrolled 238 ALD-related HCC patients underwent hepatectomy from 2011 to 2022 at the E-Da Hospital, I-Shou University. Data analyses were finalized on October, 2023. Alcoholism was defined as consuming over 20 g of ethanol each day for at least 5 years. Patients with HBsAg-positive or/and HCV-positive status were excluded. ALDH2 rs671 polymorphism was analyzed. The endpoint was HCC recurrence and overall mortality. Of the 238 patients enrolled, 196 (82.4%) were men, and the mean (SD) age was 62.3 (10.2) years. HCC recurrence occurred in 70 patients, and 64 patients died. ALDH2 rs671 polymorphism was significantly associated with HCC recurrence and mortality. The 10-year cumulative HCC recurrence and mortality rates were significantly higher in patients with the ALDH2 rs671 genotype GA/AA relative to those with the ALDH2 rs671 genotype GG. In the Cox proportional analyses, the ALDH2 rs671 genotypes GA/AA (hazard ratio [HR]: 2.66, 95% confidence interval [CI]: 1.59-4.43, <i>P</i> = 0.000) and AST ≥ 40 IU/L (HR: 1.93, 95% CI: 1.18-3.17, <i>P</i> = 0.009) were significantly associated with increased HCC recurrence. Furthermore, the ALDH2 rs671 genotype GA/AA (HR: 2.02, 95% CI: 1.17-3.49, <i>P</i> = 0.012) and age ≥ 65 years (HR: 1.67, 95% CI: 1.01-2.78, <i>P</i> = 0.048) were significantly associated with increased mortality. In conclusion, the ALDH2 rs671 genotype GA/AA is significantly associated with unfavorable clinical prognosis in ALD-related HCC after hepatectomy.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2631-2641"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a predictive model for recurrence in postoperative glottic laryngeal squamous cell carcinoma patients following adjuvant chemotherapy based on PNI, NLR, and PLR.","authors":"Baoxiao Wang, Jianming Fan, Yu Li, Yajing Wang","doi":"10.62347/CYNY8714","DOIUrl":"10.62347/CYNY8714","url":null,"abstract":"<p><strong>Objective: </strong>To identify key factors influencing postoperative recurrence in patients with glottic laryngeal squamous cell carcinoma (LSCC) and to develop a predictive model incorporating traditional clinicopathological features and novel inflammatory and immune indicators. This model aims to provide a theoretical foundation for individualized prediction of postoperative recurrence risk and support clinical decision-making.</p><p><strong>Methods: </strong>Clinical and laboratory data were collected from 614 patients with glottic laryngeal cancer who underwent surgery between April 2010 and December 2021. The study included inflammatory and immune-related indicators (such as NLR, PLR, PNI, IL-6, IL-8), alongside traditional clinical features like age, T stage, lymph node metastasis, and degree of differentiation. Univariate and multivariate logistic regression, as well as Cox regression analyses, were performed to identify factors associated with recurrence. A Nomogram model was constructed based on Cox regression results. The model's predictive performance was evaluated using ROC curves, the concordance index (C-index), and calibration curves, with validation conducted in both training and validation cohorts.</p><p><strong>Results: </strong>Multivariate analysis identified age, T stage, lymph node metastasis, degree of differentiation, IL-6, IL-8, PNI, and PLR as independent factors influencing postoperative recurrence in patients with glottic laryngeal cancer. The Nomogram model demonstrated excellent predictive performance in both the training and validation cohorts, with AUCs for 12-, 24-, and 36-month recurrence-free survival predictions of 0.887, 0.906, and 0.915 (training cohort) and 0.895, 0.906, and 0.907 (validation cohort), respectively. The model's concordance indices were 0.860 and 0.857 in the training and validation groups, respectively. Calibration curves revealed a high degree of agreement between predicted and actual outcomes.</p><p><strong>Conclusion: </strong>The Nomogram model developed in this study integrates multiple clinical and inflammatory-immune indicators, enabling accurate prediction of 12-, 24-, and 36-month recurrence-free survival rates in post-surgical patients with glottic laryngeal cancer. The model holds significant clinical value, with IL-6, IL-8, and PNI identified as crucial indicators for predicting recurrence risk, providing valuable insights for postoperative follow-up and individualized treatment strategies.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2500-2517"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of cisplatin, paclitaxel combined with high-dose methotrexate as adjuvant therapy on survival rates in osteosarcoma patients, and analysis of influencing factors.","authors":"Yixin Wang, Lang Jin, Chuanjie Zong, Xidong Zhang","doi":"10.62347/RLWT8295","DOIUrl":"10.62347/RLWT8295","url":null,"abstract":"<p><p>Osteosarcoma is a prevalent primary malignant bone tumor in young adults and adolescents, characterized by a high recurrence rate despite advancements in chemotherapy and surgical methods. This study investigated the effects of integrating high-dose methotrexate with cisplatin and paclitaxel on survival outcomes in osteosarcoma patients, and to identify prognostic factors influencing these outcomes. A retrospective analysis was conducted on 208 osteosarcoma patients treated between January 2013 and December 2018. Patients were divided into two groups: standard chemotherapy group (SC, n = 104) and cisplatin + paclitaxel + high-dose methotrexate (CPM, n = 104). The primary endpoints were progression-free survival (PFS) and overall survival (OS), while secondary endpoints included efficacy assessments. Kaplan-Meier survival curves were used to assess survival distributions, and statistical analyses were performed using SPSS 29.0. The CPM group demonstrated significantly longer PFS (16.85 ± 3.40 months vs. 15.72 ± 3.21 months, <i>P</i> = 0.015) and higher 5-year OS rates (54.81% vs. 40.38%, <i>P</i> = 0.037) compared to the SC group. Completion of chemotherapy and a response rate greater than 90% were identified as strong positive prognostic indicators. In contrast, pathologic fractures at diagnosis, lung metastases, and elevated lactate dehydrogenase levels were associated with poorer outcomes. Multivariate analysis underscored chemotherapy response and treatment adherence as independent survival predictors. The combination of cisplatin and paclitaxel with high-dose methotrexate significantly improves PFS and OS compared to standard chemotherapy. Moreover, treatment completion and achieving a chemotherapy response greater than 90% are critical factors for favorable prognosis.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2618-2630"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of YES1 kinase in regulating cisplatin resistance through iTRAQ-based quantitative proteomic analysis in urothelial carcinoma.","authors":"Chia-Che Wu, Chung-Wen Kuo, Ming-Chun Kuo, Chang-Ting Lin, Ling-Yi Xiao, Li-Chung Chang, Yi-Hua Chen, Shih-Yu Huang, Harvey Yu-Li Su","doi":"10.62347/HBJQ5692","DOIUrl":"10.62347/HBJQ5692","url":null,"abstract":"<p><p>Urothelial carcinoma (UC) is a highly metastatic cancer that frequently develops resistance to platinum-based chemotherapy, although the underlying mechanisms remain unclear. While certain genes have been implicated in UC drug resistance, their specific roles require further validation. In this study, we established a cisplatin-resistant UC cell line (BFTC909 Cis-R) and used iTRAQ analysis to compare differences in protein expression between BFTC909 Cis-R cells and their parental BFTC909 counterparts. iTRAQ mass analysis revealed decreased expression of the tyrosine kinase YES1 in BFTC909 Cis-R cells, along with reduced levels of YES1 and YAP in both BFTC909 Cis-R and T24 Cis-R cells. Moreover, we found that bladder cancer patients with higher YES1 expression had significantly better survival outcomes in our in-house cohort and two public datasets (GSE13507 and GSE169455). Treatment with dasatinib, a YES1 inhibitor, reduced cisplatin-induced cytotoxicity in UMUC-14 cells, suggesting that YES1 influences cisplatin efficacy in UC cells. Our findings indicate that YES1 plays a critical role in cisplatin resistance and may represent a promising therapeutic target in bladder cancer.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2535-2550"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction of abscopal effect combining H101 oncolytic virotherapy with tislelizumab in a patient with advanced hepatocellular carcinoma: a case report.","authors":"Danzhen Ou, Yijing Li, Jingjing Wu, Shunjie Ou, Fangwei Xie","doi":"10.62347/VSQY6496","DOIUrl":"10.62347/VSQY6496","url":null,"abstract":"<p><p>We reported a case of advanced hepatocellular carcinoma (HCC) in a patient who relapsed after first-line chemoimmunotherapy. Remarkably, the combination of H101 oncolytic virotherapy and tislelizumab successfully induced an abscopal effect. Following this treatment, the patient achieved a 24-month survival period, accompanied by complete regression of distant metastatic lesions. Distinct tumor responses were observed at different sites following H101 injection. Lesions showing regression demonstrated higher infiltration of CD3⁺ T cells, CD4⁺ T cells, and eosinophils, along with lower infiltration of neutrophils. Rapid tumor shrinkage was associated with severe local inflammation and a reduction in peripheral white blood cell counts. These findings suggest that oncolytic virotherapy may elicit an abscopal effect by activating and recruiting immune cells into the tumor microenvironment.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2650-2656"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation and predictive modeling of serum exosomal miRNAs and serological biomarkers for lymph node metastasis in gastric cancer.","authors":"Quandong Li, Fang Nie, Dezhi Huang, Yongping Lin, Junjie Wan","doi":"10.62347/AOJE4206","DOIUrl":"10.62347/AOJE4206","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the predictive potential of serum exosomal microRNAs (miRNAs) and traditional serological biomarkers for lymph node metastasis in gastric cancer and to assess their applicability in clinical practice.</p><p><strong>Methods: </strong>This retrospective study included 845 gastric cancer patients treated between January 2020 and December 2023, as the training cohort. Patients were stratified into lymph node-positive (n = 231) and lymph node-negative (n = 614) groups based on postoperative pathological evaluation. Serum exosomal miRNAs and conventional serological biomarkers were quantified and compared between groups. Multivariate logistic regression analysis was conducted to identify independent predictors. Model performance was validated using an independent test cohort comprising 277 patients (74 lymph node-positive, 203 lymph node-negative).</p><p><strong>Results: </strong>Patients with lymph node metastasis exhibited significantly elevated expression of miR-21, miR-20a, miR-27a, and miR-106a. Serological markers that were significantly higher in the lymph node positive group included carbohydrate antigen 724, carcinoembryonic antigen, hepatocyte growth factor, vascular endothelial growth factor, interleukin-6, and circulating cell-free DNA (all P < 0.05). A combined predictive model integrating both miRNA and serological data demonstrated strong diagnostic performance, with an area under the curve of 0.816 in the training cohort and 0.817 in the validation cohort.</p><p><strong>Conclusion: </strong>Serum exosomal miRNAs and serological biomarkers are significantly associated with lymph node metastasis in gastric cancer.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2579-2594"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-33 as a biomarker for disease severity in COPD with lung cancer comorbidity.","authors":"Hui Ren, Yan Cui, Xiuyun Lv","doi":"10.62347/QCSN6467","DOIUrl":"10.62347/QCSN6467","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the differences in peripheral blood levels of interleukin-1β (IL-1β), IL-6, IL-17, and IL-33 between patients with chronic obstructive pulmonary disease (COPD) and lung cancer (Comorbidity Group) and those with COPD alone (COPD Group), as well as to explore their clinical significance.</p><p><strong>Methods: </strong>Samples were collected from 133 patients with both COPD and lung cancer (Comorbidity Group) and 91 patients with COPD alone (COPD Group), diagnosed at Affiliated Hospital of Inner Mongolia Medical University between January 2022 and January 2024. Baseline data from both groups were analyzed, and peripheral blood levels of IL-1β, IL-6, IL-17, and IL-33 were measured using enzyme-linked immunosorbent assay (ELISA). The levels of these inflammatory cytokines were compared between the two groups to assess their correlation with disease severity.</p><p><strong>Results: </strong>Significant differences were observed between the Comorbidity Group and the COPD Group in terms of age (P<0.001), sex (P=0.012), duration of COPD (P=0.001), smoking history (P=0.006), glucocorticoid treatment (P=0.014), and GOLD Staging (P<0.001). IL-1β was positively correlated with RV/TLC (P=0.036), and IL-17 with FEV1 (P=0.027) in both groups. IL-6 was positively correlated with TLC in the Comorbidity Group (P=0.021). In the COPD Group, IL-33 was negatively correlated with FEV1 (P<0.001), FVC (P=0.001), FEV1/FVC (P<0.001), RV (P<0.001), and RV/TLC (P<0.001), and positively correlated with GOLD Staging (P=0.046). Multivariate logistic regression identified smoking history (P=0.045, OR=2.891), GOLD staging (P=0.028, OR=0.363), IL-33 (P=0.001, OR=27.369), FEV1/FVC (P=0.012, OR=4.291), RV (P=0.002, OR=5.429), and RV/TLC (P=0.002, OR=6.113) as independent factors distinguishing patients with comorbid COPD and lung cancer from those with COPD alone. Interaction analysis revealed no significant interaction between IL-33 and other risk factors.</p><p><strong>Conclusion: </strong>IL-33 levels were significantly higher in patients with comorbid COPD and lung cancer than in those with COPD alone. IL-33 was negatively correlated with lung function and positively correlated with GOLD Staging, suggesting its potential as a biomarker for disease severity.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2733-2749"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A hematological and inflammatory marker-based model for prostate carcinoma diagnosis.","authors":"Peiyi Guo, Garu A, Tao Chen, Yuanqing Guo, Yubo Tang, Jiangang Pan, Bin Wang, Rui Gong, Guangfu Chen, Sheng Huang","doi":"10.62347/TVFQ4646","DOIUrl":"10.62347/TVFQ4646","url":null,"abstract":"<p><p>Prostate carcinoma (PC) is the most frequently diagnosed malignancy and the third leading cause of cancer-related death among men in the United States, with over 160,000 new cases reported annually. While prostate-specific antigen (PSA) screening has advanced the early detection and management of PC, its diagnostic accuracy, particularly in distinguishing malignant from benign conditions, remains controversial. Therefore, this study aimed to improve the accuracy and efficiency of early PC diagnosis by constructing a diagnostic model based on hematological indicators. Emerging inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) were incorporated to supplement traditional PSA testing. This study employed a retrospective design and included 317 patients receiving prostate puncture at Foshan Fosun Chancheng Hospital of Guangdong Medical University between January 2019 and January 2022 as the research subjects. These patients were grouped into two categories: 126 diagnosed with PC and 191 diagnosed with benign prostatic hyperplasia, based on histopathological examination of the biopsy samples. Clinical and laboratory data were extracted from the electronic medical record system. Diagnostic markers for PC were screened by logistic regression and least absolute shrinkage and selection operator (LASSO) regression. The diagnostic performance of the model was evaluated using ROC and decision curve analysis. PSA, Neu, Mono, CRP, NLR, NAR, and CK-MB were identified as independent diagnostic indicators, effectively distinguishing PC from benign prostatic hyperplasia. The LASSO regression-based predictive model achieved an AUC of 0.850, significantly outperforming the traditional logistic regression model (AUC=0.792; P=0.042, Delong test), indicating superior diagnostic accuracy and model performance. In conclusion, the combination of traditional PSA testing and emerging inflammatory markers can significantly enhances early diagnostic accuracy for PC and the proposed model offers a promising approach for early detection and clinical decision-making.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2551-2563"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artemisinin derivatives maintain fibroblast normalization by acting on tumor-stroma interactions in oral tongue squamous cell carcinoma.","authors":"Weixing Zeng, Yawen Yang, Jia Xiong, Cui Li, Yang He, Zhihao Liang, Yongwen He","doi":"10.62347/EHVJ7118","DOIUrl":"10.62347/EHVJ7118","url":null,"abstract":"<p><p>Fibroblasts can transform into cancer-associated fibroblasts (CAFs) when continuously stimulated by cancer cells, thereby playing a crucial role in cancer progression. Growing evidence indicates that targeted therapy for CAF can influence tumor progression. Dihydroartemisinin (DHA) and artemether (ARM), semisynthetic derivatives of the natural compound artemisinin, have exhibited anticancer effects in various tumors. In this study, we found that tumor cells secreted platelet-derived growth factor-BB (PDGF-BB), which stimulated fibroblasts to transition into the CAF phenotype (cell phenotype and secretory phenotype). CAFs promote Cal-27 cell proliferation by secreting lactate. We focused on the mechanisms by which DHA and ARM affect the tumor-stroma interactions. These findings demonstrated that DHA and ARM effectively suppressed the secretion of PDGF-BB from Cal-27 cells, maintaining the normal state of hOMF and preventing the proliferative effect on Cal-27 cells. These findings were confirmed in xenograft models. Our study showed that artemisinin derivatives prevent the progression of oral tongue squamous cell carcinoma (OTSCC) by inhibiting the production of PDGF-BB in cancer cells to maintain the normal state of fibroblasts, thus providing a potential avenue for targeted OTSCC treatment.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2657-2681"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}